1 / 46

Platelet Allo-Antibody Syndromes

Donald M. Arnold MDCM, FRCPC Assist professor, McMaster University McMaster Platelet immunology Laboratory CBS Hamilton. Platelet Allo-Antibody Syndromes. 1. Troubles with this talk. “Difficulties with Platelet Transfusion, HLA Serology & Management of NAIT & PTT” Nomenclature

seth-hughes
Download Presentation

Platelet Allo-Antibody Syndromes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Donald M. Arnold MDCM, FRCPC Assist professor, McMaster University McMaster Platelet immunology Laboratory CBS Hamilton Platelet Allo-Antibody Syndromes 1

  2. Troubles with this talk • “Difficulties with Platelet Transfusion, HLA Serology & Management of NAIT & PTT” • Nomenclature • Limited evidence • Variability in practice • Serious illnesses • Costly, potentially dangerous treatments 2

  3. Learning Objectives • Understand the mechanism of platelet antigen sensitization 2. Explore pathophysiology of: • platelet refractoriness • fetal or neonatal alloimmune thrombocytopenia • post-transfusion purpura 3. Discuss management of PLT refractoriness, FNAT and PTP

  4. Human Leukocyte Antigens (HLA) 4

  5. Human Platelet Antigens (HPA) 5

  6. Human Platelet Antigens (HPA) 6

  7. Antigens on Platelets • Blood group antigens (ABO) • Common tissue antigens (HLA) • Platelet specific antigens (HPA) 7

  8. Platelet Specific Antigens • Chosen name, or name related to individual with antigen (PlA1,Zav, Gov). • Currently all antigens are designated as human platelet antigen(HPA). • Antigens numbered in order of discovery. Higher frequency allele is “a”. e.g. PLA1 = HPA-1a, PLA2 = HPA-1b Nomenclature 8

  9. Platelet Specific Antigens • To date, more than 22 platelet specific alloantigens identified, with 6 diallelic system (HPA-1, 2, 3, 4, 5, 15). Almost all are associated with a single amino acid substitution (SNP). • Antibodies against HPA-1a are most commonly implicated in NAT, PTP. 9

  10. Platelet Transfusion Refractoriness

  11. Platelet Refractoriness Definition • 1h corrected count incr < 5 – 10 x109/L • Percent PLT recovery <20% • 1h CCI < 5 x109/L x2 using ABO-identical fresh platelets • A post-transfusion platelet count that is less than expected 11

  12. Causes of PLT refractoriness • Immune • Anti-HLA, anti-ABO, anti-HPA • Non-immune • Fever • Sepsis • Splenomegaly • DIC • Bleeding • VOD • GVHD 12

  13. Immune • Alloimmunization occurs after transfusion, pregnancy, transplantation. • Alloimmunization does not mean refractory • Strategies to reduce refractoriness: • Leukoreduction • Platelet dose? • Apheresis vs. whole blood derived platelets 13

  14. TRAP (Slichter 1997) 14

  15. TRAP (Slichter 1997) 15

  16. Slichter Blood 2005 16

  17. Decline in PLT responsiveness A: In all patients (n=6334 transfusions; 533 patients) B: In HLA-antibody-negative patients (n= 5484 transfusions; 477 patients) Slichter Blood 2005 17

  18. Apheresis vs. Whole blood PLTs Heddle, Transfusion 2008 18

  19. Management AlgorithmHod BMJ 2008 19

  20. Hod BMJ 2008 20

  21. Fetal/ Neonatal Alloimmune Thrombocytopenia 21

  22. 22

  23. 23

  24. FNAT Low platelets and bleeding in a fetus or neonate caused by maternal antibodies directed against fetal platelet antigens inherited from the father. Definition: 24

  25. FNAT Incidence: 1 in 1,000 to 1 in 2,000 births 25

  26. FNAT • Most common cause of severe TCP in infant • Most common cause of ICH in term newborns • First pregnancies, without warning • Otherwise healthy babies 26

  27. NFNATAT • Fetal platelet antigen: Inherited from father • Sensitization: Transplacental • Immunization: Mother forms IgG allo-antibodies • Maternal antibodies: React with fetal platelets • Fetal platelet destruction: Spleen and RES 27

  28. Arnold et al, Trans Med Rev 2008 28

  29. Incidence of TCP at birth • <150,000 - 1 in 100 • < 50,000 - 1 in 400 • Infection • Immune mediated • Chromosomal abnormalities • <20,000 - NAT Burrows, Kelton 1993 29

  30. NAT and HDN Arnold et al, Trans Med Rev 2008 30

  31. Treatment of affected neonates • Present without warning • Require prompt recognition and treatment • IVIg (2g/kg) • Effective in 75% of affected neonates Mueller-Eckhardt C, Blut 1989 • Platelet transfusions: • Antigen-negative (maternal) platelets Allen, Blood 2007 • Random-donor platelets Kiefel et al Blood 2006 31

  32. Antenatal treatment • IVIg 1g/kg/wk (2g/kg/wk for refractory) • IVIg + corticosteroids • Intrauterine platelet transfusions • Fetal blood sampling (FBS) 32

  33. Risk-based treatment High Risk (n= 40)Standard Risk (n= 39) (previous ICH or PLT<20) (neither) IVIg vs. IVIg + predIVIg vs. pred (1g/kg/wk) (1mg/kg) (1g/kg/wk) (0.5mg/kg) PUBS (20 wks, repeat 3-8 wks) Outcome: increase in fetal platelet count Berkowitz, Bussel, 2006 33

  34. Risk-based treatment HIGH RISK Mothers (platelet count) Pre 2-8 wks Birth IVIg alone* 7,000 17,000 67,000 IVIg + pred 8,000 67,000 99,000 * One ICH Berkowitz, Bussel, 2006 34

  35. Risk-based treatment STANDARD RISK Mothers* (platelet count) Pre 3-8 wks IVIg alone >20,000 31,000 Pred alone >20,000 26,000 * 2 fetal deaths, 2 ICH Berkowitz, Bussel, 2006 35

  36. Risk-based treatment • 11 SERIOUS COMPLICATIONS OF 175 PUBS (6%) - 1 Fetal Death - 9 Emergency C-Sections (14%) 36

  37. What is the optimal management of mothers at-risk of NAT? • IVIG Cochrane collaboration 2006 • Corticosteroids Berkowitz, Bussel, 2006 • Invasive vs. non-invasive approach? • Fetal blood sampling • FBS + intrauterine PLT transfusions • Cesarean section • No FBS • Empiric treatment • Vaginal delivery 37

  38. Is there a role for screening? • N= 100,448 pregnancies screened (for HPA-1a) • Offered early c/s with compatible platelets. • 3 of 161 (6%) screen-positive infants died or had ICH; versus 10 of 51 (20%) unscreened infants. Kjeldsen-Kragh J, Blood, 2007 38

  39. Post Transfusion Purpura

  40. PTP: Clinical • Frequency: uncertain • 1 per 2 million RBCs (2008, SHOT) • Adults (~50 years); females (5x) • PLT <15 x109/L, Bleeding ++ • Onset: 9 days post blood transfusion • Recovery: 7 – 48 days after onset • Mortality ~10% (intracerebral hemorrhage)

  41. Sensitization • Sensitization by previous transfusions, pregnancy • Usually HPA-1bb recipients • Other at risk HPA genotypes

  42. SHOT(www.shotuk.org)

  43. PTP Pathogenesis • Transfusion of incompatible PLTs • Typically, anti-HPA-1a Abs • Destroy transfused and autologous PLTs • Theories: • Immune complexes • Adsorbed PLT antigens • Concomitant auto-Abs • Further research needed

  44. PTP: Treatment • Supportive: Ag-negative platelet transfusions • IVIG • Plasma exchange • Corticosteroids

  45. Summary • Platelet sensitization • HLA antibodies are ubiquitous, transient • Example: PLT refractoriness • HPA antibodies are rare, persistent • Examples: FNAT, PTP

  46. Summary • PLT refractoriness: • Consider HLA matched, XM compatible PLTs • FNAT: • Newborn PLT <20; FNAT until proven otherwise • PTP: • Severe thrombocytopenia (PLT <15) and bleeding

More Related